Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$73.79
+1.3%
$73.55
$62.75
$87.68
$228.84B0.415.11 million shs3.43 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$163.63
+0.3%
$158.68
$140.68
$169.99
$394.32B0.477.63 million shs5.76 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$31.12
-3.1%
$34.72
$29.25
$170.47
$12.03B1.866.82 million shs5.68 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.20
+0.8%
$26.06
$24.48
$31.54
$142.93B0.6139.04 million shs32.32 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$637.36
+0.2%
$683.88
$629.02
$1,211.20
$69.68B0.27673,409 shs805,912 shs
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
+1.30%-1.52%-2.29%+11.36%+8.10%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.25%+0.14%+0.54%+12.81%+3.59%
Moderna, Inc. stock logo
MRNA
Moderna
-3.11%-4.72%-7.33%-22.45%-71.86%
Pfizer Inc. stock logo
PFE
Pfizer
+0.60%-3.83%-4.55%-5.33%-9.25%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+0.24%-3.21%-9.84%-10.53%-34.04%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.9617 of 5 stars
2.65.01.70.03.40.01.3
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.4042 of 5 stars
2.33.04.23.93.52.50.6
Moderna, Inc. stock logo
MRNA
Moderna
4.1099 of 5 stars
4.01.00.04.61.42.50.6
Pfizer Inc. stock logo
PFE
Pfizer
4.9866 of 5 stars
3.33.04.24.23.33.33.1
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4.8218 of 5 stars
4.43.01.72.34.11.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
3.10
Buy$89.7521.63% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.56
Moderate Buy$171.334.71% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$59.0089.59% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.63
Moderate Buy$31.9226.67% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.76
Moderate Buy$973.1352.68% Upside

Current Analyst Ratings Breakdown

Latest REGN, MRNA, JNJ, AZN, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/5/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$159.00 ➝ $171.00
2/19/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
2/19/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$96.00 ➝ $78.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$40.00 ➝ $40.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$111.00 ➝ $45.00
(Data available from 3/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.07B4.23$6.26 per share11.79$13.18 per share5.60
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$88.82B4.44$13.45 per share12.17$29.69 per share5.51
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B3.76N/AN/A$28.33 per share1.10
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.25$3.95 per share6.38$15.81 per share1.59
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.20B4.91$41.85 per share15.23$268.50 per share2.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.2632.6514.761.4213.01%32.23%12.31%4/29/2025 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$6.6524.6114.782.5618.20%34.24%13.63%4/15/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4117.878.320.6412.62%19.47%8.09%4/29/2025 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.41B$38.2816.6516.762.3431.07%16.32%12.76%4/29/2025 (Estimated)

Latest REGN, MRNA, JNJ, AZN, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/24/2025N/A
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.10N/AN/AN/AN/AN/A
4/15/2025N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.59N/AN/AN/A$21.65 billionN/A
2/6/2025Q4 2024
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.10$1.05-$0.05$0.48$14.19 billionN/A
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
2/4/2025Q4 24
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$11.21$12.07+$0.86$8.06$3.76 billion$3.79 billion
1/22/2025Q4 2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$1.99$2.04+$0.05$1.41$22.44 billion$22.52 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$2.062.79%+1.98%91.15%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.963.03%+5.43%74.59%63 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.83%+2.50%121.99%16 Years
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$0.880.14%N/A2.30%N/A

Latest REGN, MRNA, JNJ, AZN, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/6/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
semi-annual$1.032%2/21/20252/21/20253/24/2025
2/20/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.880.53%2/20/20252/20/20253/20/2025
1/2/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.43%2/18/20252/18/20253/4/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.65
0.93
0.74
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.43
1.11
0.86
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.09
4.73
3.95

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
7.48%
CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
83,5003.10 billionN/AOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
152,7002.41 billion2.40 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
11,900109.33 million101.15 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$73.79 +0.95 (+1.30%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$72.92 -0.87 (-1.18%)
As of 03/28/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$163.63 +0.50 (+0.31%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$163.36 -0.27 (-0.17%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna stock logo

Moderna NASDAQ:MRNA

$31.12 -1.00 (-3.11%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$31.22 +0.11 (+0.34%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer stock logo

Pfizer NYSE:PFE

$25.20 +0.19 (+0.76%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$25.14 -0.07 (-0.26%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$637.36 +1.53 (+0.24%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$631.32 -6.04 (-0.95%)
As of 03/28/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.